Use of compound aprepitant in preparation of drug for preventing or treating African swine fever (ASF)

US11883411B2 · kind B2 · utility

Assignee

• LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES · CN

Inventors

• Keshan Zhang · Huangyang, CN
• Haixue Zheng · Huangyang, CN
• Huimei Cui · Lanzhou, CN
• Bo Yang · Zhejiang, CN
• Hong Tian · Zhengzhou, CN
• Zixiang Zhu · Lanzhou, CN
• Tao Feng · Shanghai, CN
• Fan Yang · Brookline, US
• Weijun Cao · Huangyang, CN
• Xusheng Ma · Lanzhou, CN
• Yi Ru · Lanzhou, CN
• Jianhong Guo · Lanzhou, CN
• Xiangtao Liu · Lanzhou, CN

Key dates

• Filing date: Aug 25, 2022
• Grant date: Jan 30, 2024
• Expiry date: Aug 25, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure belongs to the technical field of African swine fever (ASF) treatment, in particular to use of a compound aprepitant in prevention or treatment of the ASF. In the present disclosure, it is found that the compound aprepitant can significantly inhibit replication of an African swine fever virus (ASFV); in addition, it is found that the aprepitant inhibits transcription and protein expression of D1133L, and reduces transcription and protein expression levels of p30 and p72, preventing virus invasion on host cells. Therefore, the compound aprepitant can be used to inhibit early and late infection of the ASFV. Accordingly, the compound aprepitant can be used to prevent or treat the ASF.